Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 3:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 517 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sepsis Clear all

Conditions: Sepsis
Interventions: Observation; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Sepsis, Hypotension
Interventions: Treatment Starling SV monitor; Device
Lead sponsor: Cheetah Medical Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 11
States / cities: San Francisco, California • Denver, Colorado • Atlanta, Georgia + 7 more

Conditions: Severe Sepsis
Interventions: Not listed
Lead sponsor: Bluejay Diagnostics, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 200 participants
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Severe Sepsis
Interventions: S.A.F.E.BT; Device
Lead sponsor: B. Braun Medical Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: Lexington, Kentucky • Baltimore, Maryland

Conditions: Nephrolithiasis, Urinary Tract Infection (UTI), Sepsis
Interventions: Nitrofurantoin 100 MG, 7d, Gentamicin, 5mg/kg, Ampicillin 2g, Nitrofurantoin 100 mg, 48 hrs, Gentamicin, 80 mg, 7d, Gentamicin, 80 mg, 48hr; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: Not listed
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: San Diego, California

Conditions: Biomarkers, Acute Kidney Injury, Sepsis
Interventions: Not listed
Lead sponsor: Nutromics; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Oakland, California • San Francisco, California • Stanford, California + 2 more

Conditions: Sepsis, Gastroenteritis, Dehydration
Interventions: SonoSite Maxx Series Ultrasound System; Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: Up to 21 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Septic Shock
Interventions: Near-infrared spectroscopy assessment; Diagnostic Test
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bacterial Infections
Interventions: Not listed
Lead sponsor: Methodist Health System; Other
Eligibility: 18 Years to 85 Years
Enrollment: 77 participants
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Respiratory Distress Syndrome, Adult
Interventions: BIO-11006, Placebo; Drug
Lead sponsor: BioMarck Pharmaceuticals, Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 5
States / cities: Chicago, Illinois • Chapel Hill, North Carolina • Winston-Salem, North Carolina + 2 more

Conditions: Pneumonia, Ventilator-Associated, Pneumonia, Bacterial, Pneumonia, Hospital-Acquired
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: Not listed
Enrollment: 7,530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 12 more

Conditions: Sepsis
Interventions: Not listed
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2014
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Autoimmune Diseases, Lupus Erythematosus, Systemic, Communicable Diseases
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2028
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Sepsis Syndrome, Sepsis, Severe Sepsis, Septic Shock, Infection
Interventions: Not listed
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 1,304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Brooklyn, New York • New York, New York

Conditions: Brain Injuries, Dementia, Myopathies, Muscle Disorders
Interventions: Behavioral: Physical and functional rehabilitation, Behavioral: Cognitive, physical, & functional rehabilitation; Behavioral
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Severe Sepsis, Respiratory Failure
Interventions: Not listed
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Acute Lung Injury, Acute Respiratory Distress Syndrome
Interventions: Not listed
Lead sponsor: Sturgill; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Disability, Physical Activity, Aging, Critical Illness
Interventions: Not listed
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Sepsis
Interventions: Not listed
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Severe Sepsis, Acute Heart Failure
Interventions: Mespere Venus 1000 Non-Invasive CVP System; Device
Lead sponsor: Mespere Lifesciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI), Hospital Acquired Pneumonia (HAP), Complicated Urinary Tract Infection (cUTI), Sepsis, Ventilator Associated Pneumonia (VAP)
Interventions: Cefiderocol, Best Available Therapy; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 6
States / cities: Hartford, Connecticut • Newark, Delaware • Chicago, Illinois + 3 more

Conditions: ARDS, Sepsis, Pneumonia
Interventions: Blood collection, Urine Collection, Nasal, oral, and rectal swabs, Stool collection, Heat Moisture Exchange Filter collection, Tracheal Aspirate sample collection, Non-bronchoscopic bronchoalveolar lavage (NBBAL), Surveys, Short physical performance battery, Hand grip strength, CNS Vital Signs, Muscle Ultrasound, Muscle Strength, Spirometry, Lung Diffusion Testing (DLCO), Chest CT Scan; Other · Procedure · Radiation
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 20
States / cities: Fresno, California • Palo Alto, California • San Francisco, California + 12 more

Conditions: Sepsis
Interventions: Not listed
Lead sponsor: Measure Labs, Inc.; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Durham, North Carolina • Raleigh, North Carolina

Conditions: Subarachnoid Hemorrhage (SAH)
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Jacksonville, Florida

Search by objective public record fields.

Dynamics of Organ Damage and Immune Exhaustion During Sepsis

Fluid Responsiveness Evaluation in Sepsis-associated Hypotension

Symphony IL-6 Study in Patients at Risk of Severe Sepsis

S.A.F.E.BT System Extracorporeal Treatment With DIAPACT CRRT

Endourology Disease Group Excellence (EDGE) Consortium: Antibiotics (Abx) for Percutaneous Nephrolithotomy (PCNL) Part 2

Vancomycin Exposure and Biomarker Tracking Using Real-time Monitoring of Interstitial Fluid

Utility of Ultrasound Assessment of the Inferior Vena Cava in Patients With Sepsis and Dehydration

Near Infrared Spectroscopy (St02)

An Evaluation of a Antimicrobial Stewardship Recommendation Bundle for Staphylococcus Aureus Bloodstream Infections

Evaluation of Safety & Efficacy of BIO-11006 Inhalation Solution in Patients With ARDS

CTTI Risk Factors for HABP/VABP Study

Indicators of Inflammation and Coagulation in Sepsis

Comparative Autoantibody and Immunologic Cell Marker Study

Mitochondrial DNA as a Biomarker of Sepsis Severity

ACT-ICU Study: Activity and Cognitive Therapy in the Intensive Care Unit

Muscle Atrophy in Patients With Severe Sepsis

The ASTERS Study: Assessing the Role of Sphingolipids in AcuTE Respiratory Distress Syndrome (ARDS)

Actigraphy to MEasuRe Intensive Care Unit Activity

SHOCK US STUDY: Fluid Responsiveness in Sepsis Measured by Ultrasonography

Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial

Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens

The APS Phenotyping Study

Discharge Readmission Analysis and Management in Sepsis (DReAMS-2)

Serum Procalcitonin